Skip to main content

Table 2 Correlation of nucleus and cytoplasmic ERβ2 and ERβ5 with clinicopathological parameters in ovarian cancer

From: Differential expression of estrogen receptor subtypes and variants in ovarian cancer: effects on cell invasion, proliferation and prognosis

Characteristics Case (n) Nucleus ERβ2 Cytoplasmic ERβ2   Nucleus ERβ5   Cytoplasmic ERβ5  
   Mean ± SD p-value Mean ± SD p-value   Mean ± SD p-value   Mean ± SD p-value  
Stage (FIGO)
 Early (I-II) 49 5.46 ± 1.50   3.90 ± 1.43    6.61 ± 1.10    1.86 ± 1.67   
 Late (III-IV) 37 5.65 ± 1.60 0.936* 3.78 ± 1.40 0.701*   7.11 ± 1.22 0.030 * 1.46 ± 1.77 0.165*  
Histological grade
 Low (1–2) 56 5.49 ± 1.76   3.84 ± 1.58    6.88 ± 1.06    1.70 ± 1.72   
 High (3) 33 5.64 ± 1.27 0.996* 3.88 ± 1.32 0.784*   6.82 ± 1.29 0.751*   1.67 ± 1.80 0.904*  
Histology
 Serous 35 5.80 ± 1.68   4.06 ± 1.24    6.89 ± 1.37    1.40 ± 1.77   
 Clear Cell 17 5.71 ± 1.26   3.00 ± 2.00    7.29 ± 1.11    1.06 ± 1.44   
 Mucinous 9 4.63 ± 2.26   3.25 ± 1.49    6.22 ± 0.67    1.78 ± 1.64   
 Endometrioid 29 5.40 ± 1.35 0.608 4.27 ± 1.14 0.005   6.70 ± 0.92 0.079   2.33 ± 1.73 0.071  
 Serous/Clear Cell 52 5.77 ± 1.54   3.71 ± 1.59    7.02 ± 1.29    1.29 ± 1.66   
 Mucinous/Endometrioid 38 5.24 ± 1.58 0.237* 4.05 ± 1.27 0.246*   6.59 ± 0.88 0.039 * 2.21 ± 1.70 0.013 *
 Clear Cell 17 5.71 ± 1.26   3.00 ± 2.00    7.29 ± 1.11    1.06 ± 1.44   
 Non-Clear Cell 73 5.51 ± 1.64 0.580* 4.05 ± 1.25 0.001 * 6.73 ± 1.14 0.095*   1.82 ± 1.77 0.134*  
Chemosensitivitya
 Sensitive 63 5.56 ± 1.57   3.64 ± 1.36    6.84 ± 1.13    1.67 ± 1.72   
 Resistant 13 5.92 ± 1.38 0.595* 4.46 ± 1.66 0.105*   6.92 ± 1.12 0.387*   1.69 ± 1.93 0.846*  
  1. Those with significant P-values are underlined. ↑Increase expression. ↓Decrease expression
  2. *Mann–Whitney test; Kruskal–Wallis rank test
  3. aChemosensitive-patients remained disease free more than 6 months after completion of first-line chemotherapy
  4. Intensity values are expressed as “Histoscores” as specified in Methods